Highly effective (HE) disease‐modifying therapies (DMTs) reduce relapse‐associated worsening (RAW) and progression independent of relapse activity (PIRA). Natalizumab (NTZ) and anti‐CD20 agents show similar efficacy on relapse suppression, but long‐term comparative data on PIRA are limited. We aimed to compare PIRA acc...
L. Palazzo, F. Clarelli, Michele Surano et al.· European Journal of Neurolog...· 0 citations
Abstract Functional network reorganization supports compensatory mechanisms in multiple sclerosis, but ageing and later disease onset may alter this balance. Late-onset multiple sclerosis (age at onset ≥50 years) represents a relevant subgroup to examine how disease onset in older age is associated with functional conn...
Nicolò Tedone, P. Valsasina, A. Meani et al.· Brain Communications· 0 citations
Multimodal MRI analysed with SuStaIn identified reproducible subtypes of multiple sclerosis with clinically meaningful differences in phenotype, age at onset, disability, and relapse-independent progression, while cognitive impairment was related to advancing SuStaIn stage within each subtype.
P. Preziosa, L. Storelli, F. Clarelli et al.· Brain : a journal of neurolo...· 0 citations
Inhibitory neurons emerged as a key target cell type for MS-associated variants, with seven loci, including STAT3, displaying altered expression only in these cells, suggesting that MS susceptibility may reflect reduced central nervous system resilience to inflammatory challenges.
Lu Zeng, Atlas Khan, Kathryn C. Fitzgerald et al.· Nature Genetics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.